-
Views
-
Cite
Cite
Jeffrey T. Schouten, Amy Krambrink, Heather J. Ribaudo, Anne Kmack, Nancy Webb, Cecilia Shikuma, Daniel R. Kuritzkes, Roy M. Gulick, Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095, Clinical Infectious Diseases, Volume 50, Issue 5, 1 March 2010, Pages 787–791, https://doi.org/10.1086/650539
- Share Icon Share
Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious.
Clinical trials registration. NCT00013520.